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Background: 5-lipoxygenase (5-LO) is a key enzyme in the synthesis of leukotrienes and 5-Oxo-6E,8Z,11Z,14Z-
eicosatetraenoic acid (oxoETE). These inflammatory signaling molecules play a role in the pathology of asthma
and so 5-LO inhibition is a promising target for asthma therapy. The 5-LO redox inhibitor zileuton (Zyflo IR/CRW)
is currently marketed for the treatment of asthma in adults and children, but widespread use of zileuton is
limited by its efficacy/safety profile, potentially related to its redox characteristics. Thus, a quantitative, mechanistic
description of its functioning may be useful for development of improved anti-inflammatory targeting this
mechanism.
Results: A mathematical model describing the operation of 5-LO, phospholipase A2, glutathione peroxidase and
5-hydroxyeicosanoid dehydrogenase was developed. The catalytic cycles of the enzymes were reconstructed
and kinetic parameters estimated on the basis of available experimental data. The final model describes each
stage of cys-leukotriene biosynthesis and the reactions involved in oxoETE production. Regulation of these
processes by substrates (phospholipid concentration) and intracellular redox state (concentrations of reduced
glutathione, glutathione (GSH), and lipid peroxide) were taken into account. The model enabled us to reveal
differences between redox and non-redox 5-LO inhibitors under conditions of oxidative stress. Despite both redox
and non-redox inhibitors suppressing leukotriene A4 (LTA4) synthesis, redox inhibitors are predicted to increase
oxoETE production, thus compromising efficacy. This phenomena can be explained in terms of the
pseudo-peroxidase activity of 5-LO and the ability of lipid peroxides to transform 5-LO into its active form even in
the presence of redox inhibitors.
Conclusions: The mathematical model developed described quantitatively different mechanisms of 5-LO
inhibition and simulations revealed differences between the potential therapeutic outcomes for these
mechanisms.Background
Leukotrienes are key inflammatory mediators associated
with pathological states of inflammation in diseases such
as asthma and allergic rhinitis and play a pivotal role in
normal host defense [1]. They have been shown to pro-
mote leukocyte chemotaxis and activation, vascular tone
and permeability, smooth muscle contractility and im-
mune function. 5-lipoxygenase (5-LO) is the key enzyme* Correspondence: karelina@insysbio.ru
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reproduction in any medium, provided the orof leukotriene biosynthesis and so is a promising target
for drug development [2,3].
5-LO is expressed predominantly in leukocytes and is
responsible for the synthesis of both leukotriene A4 (LTA4)
and 5(S)-hydroperoxy-6,8,1l,14-(E,Z,Z,Z)-eicosatetraenoic
acid (HP) [4-6]. The reaction scheme is given in Figure 1.
There are two steps in this reaction: oxygenation of ara-
chidonic acid (AA) using O2 to produce HP and the
dehydration of the hydroperoxide intermediate, to pro-
duce the epoxide, leukotriene A4 (LTA4). HP can be fur-
ther converted either to 5-hydroxyeicosatetraenoic acid
(HT) by glutathione peroxidase (GPx) [7,8]. HT, in turn,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Schematic representation of Leukotriene and oxoETE synthesis model (“LOS model”). The reactions occurring with 5-LO are in
the dashed red circle. Blue rectangular represents metabolites which are variables of “LOS model”. Pink colour indicates complex of 5-LO and HP.
Dashed arrows stand for degradation processes.
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acid (oxoETE) by 5-hydroxyeicosanoid dehydrogenase
(HEDH) [9]. oxoETE is produced by various cells includ-
ing neutrophils, eosinophils, and monocytes [10] and acts
as a potent chemo-attractant for these cell types. For
example, 5oxoETE stimulates eosinophil migration and
tissue infiltration 30 fold more potently than leuko-
triene B4 (LTB4) [11], and also increases intracellular
calcium (Ca2+) concentration and actin polymerization
in eosinophils [10].
5-LO activity is controlled by the intracellular Ca2+
concentration and the cellular redox state [4-6,12,13].
The redox state modulates activity via the iron (Fe) atom
located in the catalytic site of the enzyme. HP and other
lipid peroxides are able to oxidize the Fe atom from Fe2+(ferrous state) to the active Fe3+ (ferric state). Consistent
with this the addition of glutathione peroxidase (GPx)
inhibits formation of products of 5-LO catalyzed reac-
tions in vitro [13]. Similar to other lipoxygenases, 5-LO
also demonstrates redox state dependent hydroperoxidase
activity [14]: ferrous 5-LO reacts with lipid-hydroperoxide
to form ferric 5-LO, an oxygen-centered lipid radical and
hydroxide ion. Additionally, 5-LO activity, in the pres-
ence of Ca2+, is increased by structural stabilization via
ATP (adenosine-5’-triphosphate) without ATP hydrolysis,
microsomal membranes or phosphatidylcholine vesicles
(PtdCho) [13]. Mitogen activated protein MAP kinase
cascade activity, nuclear import and export of 5-LO,
interaction with coactosin-like protein (CLP), 5-LO
activating protein (FLAP) and phosphorylation of the
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of 5-LO activity, also have been reported to modulate
it’s activity [12].
Most of the known inhibitors of the 5-LO act on the
basis of a redox-mechanism or by chelation of the Fe
atom of 5-LO [3]. Redox inhibitors reduce the Fe atom
from active ferric state to the inactive ferrous state. The
complexity of 5-LO regulation and the multiple reaction
paths suggests that redox and non-redox inhibitors may
have qualitatively and quantitatively different effects on
the products of 5-LO catalyzed reactions.
Zileuton (Z, N-(l-benzo(b)thien-2-ylethyl)-N-hydroxyurea
or Zyflo IR/CRW), is a redox inhibitor of 5-LO currently
approved for the daily treatment of asthma in adults and
children [15]. Zileuton has a sub-optimal pharmacoki-
netic and pharmacodynamic profile resulting in a high
total daily dose (2400mg) and frequent dosing (4 times
a day [q.i.d] for Zyflo IRW and twice a day [b.i.d] for
Zyflo CRW) [16], plus a potential for hepatotoxicity [17].
Therefore, the development of a medicine with more
convenient dosing regimen may maximise the benefits
of inhibiting the leukotriene pathway and provide efficacy
superior to that obtained with zileuton. PF-4191834,
4-(3-(4-(1-methyl-1H-pyrazol-5-yl)phenylthio)phenyl)-
tetrahydro-2H-pyran-4-carboxamide (PF), is a novel
non-iron chelating, non-redox, 5-LO inhibitor under
investigation for the treatment of various inflammatory
conditions [18]. The presence of significant data in the
public domain for zileuton and PF suggested that devel-
opment of a mathematical model would allow insight
into the potential differential effects of non-redox and
redox inhibitors. To characterize these potential effects
it was necessary to attempt to capture the key properties
of the entire pathway and its interactions in inflamma-
tory states Therefore, a detailed mathematical model,
describing the processes of 5-LO mediated catalysis reg-
ulation (self-inactivation, effect of redox state of the
medium) was developed.
Several mathematical models of 5-LO have already
been reported, for example a model describing the inhib-
ition of lipoxygenase activity by one of the substrates of
the enzyme, AA, by Aharony et al. [19]. In this model, 5-
LO is able to bind 2 molecules of AA simultaneously
(one molecule in the catalytic site and other molecule in
the additional regulatory site) which renders the enzyme
catalytically inactive. However, LTA synthesis and the
pseudo-peroxidase reaction have not been taken into ac-
count in this model. An alternative model of reticulocyte
lipoxygenase was developed with 9,12(Z,Z)-octadecadienoic
acid (linoleic acid) as substrate [20]. This model did take
into account both the activation of the enzyme by prod-
uct, hydroperoxy derivative of fatty acid, and inhibition of
5-LO with substrate, polienoic fatty acid. However, the sub-
strate inhibition was described in terms of a competitivemechanism, binding to inactive form of 5-LO thus pre-
venting its activation, and the LTA4 synthase activity of
the enzyme was not captured. Additionally, none of the
models describe the reversible inactivation of 5-LO with
HT [21] and irreversible inactivation with LTA4 [22].
The rate laws for lipoxygenase and LTA4 synthase
reactions were derived by Yang et al. [23], where the in-
fluence of various inhibitors of 5-LO and cyclooxygenase
on AA metabolism were determined. These rate equa-
tions take into account the inhibition of 5-LO activity by
LTA4, HP and HT. However, the inhibition with LTA4
was also described as reversible and the substrate inhib-
ition, product activation and pseudo-peroxidase activity
of 5-LO were not taken into account.
Therefore, an opportunity exists to develop a more
detailed model of 5-LO activity which describes all the
activities of the enzyme and their regulation by sub-
strates and products. The main purpose of this paper is
to summarize the development of a detailed mathemat-
ical model of 5-LO operation, its application to describe
the production of LTA4 and oxoETE, and to study the
differences between redox and non-redox inhibitors. The
“LOS (Leukotriene-OxoeETE-Synthesis) model” (Figure 1)
includes four enzymes: 5-LO, cytosolic phospholipase
A2 (cPLA2), GPx and HEDH and describes the major
interactions between the components of the system (for
example, the influence of glutathione concentration on
5-LO activity). We used the “LOS model” to predict the
dose-responses of various inflammatory mediators to
redox and non-redox inhibitors and provide a mechanistic
explanation for the differences between them.
Methods
Model construction
The “LOS model” describing LTA4 and oxoETE produc-
tion in leukocytes includes reactions catalyzed by 5-LO,
cPLA2, GPx, HEDH and degradation of HT, oxoETE and
LTA4. Since all leukotrienes are synthesized from LTA4,
analysis of 5-LO catalyzed LTA4 production was deemed
sufficient to evaluate the impact of 5-LO on leukotriene
production. Catalytic cycles for each of the enzymes were
constructed and rate equations describing the dependence
of reaction rate on concentrations of substrates, products
and effectors were derived utilizing literature data.
The kinetic model of 5-LO
Known experimental data and hypotheses used for the
model development
In this study, we used the following available experimen-
tal data and facts on structural and functional properties
of 5-LO:
1. AA inhibits 5-LO activity in lipoxygenase reaction at
high concentrations (substrate inhibition) [24].
Figure 2 Examples of notations of 5-LO states. Notations in
kinetic schemes are given at the left and in the text and equations
are given at the right: a) ferric state of 5-LO with Ca2+ and HT
bound to catalytic site of the enzyme; b) ferrous state with Ca2+
bound; c) sum of concentrations of ferric state with and without
Ca2+ bound and with HT and AA bound.
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3. 5-LO is self-inactivating [25]. Glutathione peroxidase
and glutathione protect the enzyme from
inactivation and lipid peroxides eliminate the
protective effect of glutathione.
4. HT is a reversible inhibitor of 5-LO [21].
5. LTA4 can inactivate 5-LO irreversibly [22].
6. The Fe atom in the catalytic site exists in two
possible states Fe2+ and Fe3+. Fe3+ is the catalytically
active state. Transition between Fe2+ and Fe3+ states
proceeds via oxidation by lipid peroxides, including
HP [12]. Reduction from Fe3+ to Fe2+ state can be
mediated by redox inhibitors (zileuton).
7. Oxidation of the enzyme (Fe2+ → Fe3+ transition) is
influenced by Ca2+ ions [25].
8. Endogenously generated 5-HP is the preferential
substrate for the 5-LO mediated LTA-synthase
reaction [26].
9. ATP and membrane binding are necessary for 5-LO
activation [13].
During model building and simplification, the follow-
ing assumptions were made:
a. There are two sites for AA binding: the catalytic site
and regulatory site. HT is a competitive inhibitor at
the catalytic site.
b. Binding of AA to the regulatory site results in
formation of dead-end complexes with 5-LO.
c. Binding of AA and HT to the catalytic site are fast
reactions in comparison to product formation.
d. Oxidation and reduction of 5-LO (transition between
Fe2+ and Fe3+) can result from (i) interaction with
lipid peroxides or (ii) “spontaneously” (by means of
interaction with oxidative or reducing factors: O2,
H2O2, thiol groups etc.).
e. Ca2+ is able to bind to the catalytic site, but it
influences only oxidation and reduction reactions,
thus kinetic parameters of other reactions of catalytic
cycle remain unchanged.
f. Binding of Ca2+ and redox-inhibitors (Z) are fast
reactions in comparison to the other reactions of the
catalytic cycle.
g. Redox inhibitors are only able to bind to the catalytic
site of 5-LO and only when it is not occupied with
other factors.
h. The binding of redox inhibitors to the catalytic site
blocks the binding of other factors .
i. The regulatory site is able to bind AA only if
following conditions are fulfilled: (i) 5-LO is in Fe3+
state and (ii) the enzyme is not bound to a redox-
inhibitor.
j. The oxygenase, pseudoperoxydase and LTA4
synthase activities of 5-LO were simplified by notdescribing electron transfer and oxygen binding.
Instead, it was assumed that the oxygen
concentration is in saturation, i.e., it is not a
parameter of the model.
k. To decrease the number of unknown parameters in
our model we have assumed that binding of AA to
the regulatory site of 5-LO does not influence the
binding of AA, HP and HT to the catalytic site (see
Additional file 1: Appendix 1).
l. Interaction with MAP kinases, FLAP, CLP and
transport of 5-LO to the nucleus have not been taken
into account in the model.
Catalytic cycle of 5-LO
Figure 2 shows schematic representation of the enzyme
states considered in the model. In the ferric state 5-LO
is able to bind any substrates/products/inhibitors at its
catalytic and regulatory sites. This state of 5-LO was
represented as a square with a triangle underneath the
square. The square designates the catalytic site of the
enzyme and the triangle represents the regulatory site.
The regulatory site can be found in 2 states: free or AA
bound. The catalytic site of 5-LO is able to bind AA,
HT, HP, PF (non-redox inhibitor), Z (redox inhibitor).
As an example Figure 2(a) shows the HT and AA bound
enzyme state. All the above mentioned compounds com-
pete for the substrate binding part of the catalytic site.
In addition to the substrate/product (AA, HP) and com-
petitive inhibitors (HT, PF and Z) the catalytic site of 5-
LO is able to bind Ca2+ (as shown in Figure 2(a)) which
does not compete with AA, HT, HP, PF and Z.
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found in a total of 12 states: free of any substrate/com-
petitor and with AA, HT, HP, PF, Z bound all of which
can be found with and without Ca2+ bound. On the basis
of this analysis we can conclude that catalytic cycle
of 5-LO includes 24 potential states (See Additional
file 2: Appendix Figures A1 and A2). The ferrous state
(Fe2+) of 5-LO is not able to bind any substrate/product/
inhibitor at the catalytic or regulatory site but it is able to
bind Ca2+ at the catalytic site (see Figure 2(b)). Thus,
total catalytic cycle includes 26 states of 5-LO. Since in
derivation of the rate equations describing 5-LO activities
we have used new variables representing sums of states
of 5-LO, notations for such sums have also been intro-
duced (Figure 2(c)). In the equations and text of this
paper we have used the simplified notations of the 5-LO
states (see Figure 1).
Transitions between the states are described in ac-
cordance to mass action law and can be either reversible
(for example, binding AA to catalytic site) or irreversible
(for example, the LTA-synthase reaction). Moreover,
these processes can be either relatively fast or slow
depending on the values of rate constants obtained from
experimental data fitting. This grouping of all processes
into two sets (fast and slow processes) allowed us to
reduce the initial complexity of the catalytic cycle and
derive rate equations describing the operation of 5-LO
according to the methods described in [27].Figure 3 Reduced catalytic cycle of 5-LO. Blue rectangular represents m
states corresponds to Figure 2. Letters with indexes designate effective rateSchematic visualization of the total catalytic cycle is
not convenient because of the complexity (26 nodes/
states and tenths of transitions between them). To recon-
struct a reduced total catalytic cycle and derive rate equa-
tions we employed a step-by-step strategy described in
Additional file 1: Appendix 1. As a result we have devel-
oped a reduced catalytic cycle (Figure 3) describing oxy-
genation, dehydration and pseudoperoxidase activities
of 5-LO. On the basis of this reduced catalytic cycle,
we have derived rate equations (1–7) describing 5-LO
mediated AA consumption (VAAcons
5LO ), 5-HP production
in oxygenase reaction (VHPcons
5LO ), HT production and HP
consumption in pseudoperoxidase reaction (VHPcons
5LO ), all
other lipid peroxide (LOOH) consumption in pseudo-
peroxidase reaction [VLOOHcons
5LO ] and LTA4 production
(VLTAsyn
5LO ):



























ð4Þetabolites which are variables of “LOS model”. Designation of enzyme
constants (see Additional file 1: Appendix 1).
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Since 5-LO undergoes irreversible inactivation, the
concentration of active enzyme tends to zero with time
and, consequently, all enzyme catalyzed reactions be-
come equal to zero. In vivo, regulatory mechanisms con-
trol intracellular 5-LO production de novo [13]. To
obtain non-zero steady state concentrations of 5-LO
states and, consequently, to derive the rate equations
describing the activities of 5-LO, we did not consider
self-inactivation of the enzyme and have not taken into
account processes responsible for 5-LO production de
novo. Under these assumptions the total concentration of
active enzyme (Fa) is equal to total enzyme concentration
and Fa is a parameter of the model. Additionally,identification of model parameters using in vitro experi-
mental data was performed on the basis of a model which
takes into account self-inactivation of 5-LO with time
(see Additional file 1: Appendix 1.5). Under these condi-
tions Fa represents the sum of active states of 5-LO and
changes with time. All rate equations were derived on the
basis of the quasi-steady state approach [27].
The kinetic model of phospholipase A2
Calcium-dependent phospholipase A2 (cPLA2) catalyzes
the production of AA from phospholipids (PL) in the
cell membrane. Elevations in the cellular calcium con-
centration significantly stimulate cPLA2 activity. On the
basis of several models of the enzyme developed previ-
ously and available experimental data [28,29] we have
derived the rate equation for cPLA2 to be (VAA
PLA2, see











The kinetic model of glutathione peroxidase
GPx enzyme reduces HP to HT. This reaction requires
glutathione as a cofactor [7,8]. The stoichiometry of the
reaction catalyzed by the enzyme is as follows:
HP þ 2 GSH ¼ HT ¼ GSSG ð20Þ
GPx catalyzes this reaction in accordance to the Ping-
Pong mechanism and the derivation of the rate equation
for GPx is given in Additional file 1: Appendix 3:

































The kinetic model of 5-hydroxyeicosanoid dehydrogenase
HEDH catalyzes the conversion of HT into oxoETE. The
mechanism of HEDH is considered as Bi-Bi Ping-Pong,
with NADP as the second substrate [9]. Derivation of
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Appendix 4:














































The LTA4 and oxoETE synthesis model (“LOS model”)
To build the “LOS model” we utilized the rate equations
describing the activities of 5-LO, phospholipase A2,
glutathione peroxidase and 5-hydroxyeicosanoid de-
hydrogenase as given above. The kinetic scheme of the
“LOS model” is shown in Figure 1. In accordance with
the scheme, AA binding to 5-LO is converted to HP via
the lipoxygenase reaction. As a result a complex of 5-LO
and HP is formed. HP can be either released from the
complex (VHPsyn
5LO ) or used to form LTA4 via the LTA4-
synthase reaction VLTAsyn
5LO . Additionally, LTA4 can be
produced from free HP in the absence of AA (see sequence
of reversible reaction VHPsyn
5LO and irreversible reaction
VLTAsyn
5LO ). To present all these process correctly the inter-
mediate state of the enzyme (Ca)FHP
(AA) (complex 5-LO with
HP) was added to the kinetic scheme. The concentration
of the state (Ca)FHP
(AA) is not a variable of the model, i.e.
there are no differential equations describing the time
dynamics of (Ca)FHP
(AA). However, in accordance with the
quasi-steady state approach chosen to describe 5-LO oper-
ation in the “LOS model” (and, consequently, applied to
derive rate equations of various 5-LO activities) concen-
tration of state (Ca)FHP
(AA) is expressed in terms of variables
of the “LOS model” (see Additional file 1: Appendix 1).
To avoid unlimited accumulation of metabolites
resulting from constant influx of AA we have introduced
processes of degradation of HT, oxoETE and LTA4
(VHTd, VLTAd and VoxoETEd) in the model. The reaction
rates of these processes are described in accordance with
mass action law (Additional file 1: Appendix 5). Add-
itionally, concentrations of PL, lipid peroxide LOOHand its reduced product LOH, reduced (GSH) and oxi-
dized (GSSG) glutathione, and reduced and oxidized
forms of NADPH are considered as parameters of the
model, i.e., do not change with time. The values for
the intracellular concentrations of GSH, GSSG,
NADPH and NADP were taken from the following
sources [30-34]. The concentration of LOOH has ei-
ther been chosen on the basis of known experimental
conditions or has been varied to describe various oxi-
dative states of the cells.
Based on all the above assumptions the system of




¼ VPLA2AA  V 5LOAAcons ð23Þ
dHP
dt
¼ V 5LOHPsyn  V 5LOHPcons  VGPx ð24Þ
dHT
dt
¼ V 5LOHPcons þ VGPx  VHEDH  VHTd ð25Þ
dLTA4
dt
¼ V 5LOLTAsyn  VLTAd ð26Þ
doxoETE
dt
¼ VHEDH  VoxoETEd ð27Þ
Description of the parameters of the “LOS model” and
experimental data used for their identification
According to assumption L of the section “Known
experimental data and hypotheses used for the model
development”, some parameters were equated with
each other (see 1.4). Thus, for 5-LO 17 independent
parameters remained, among them 11 equilibrium
constants and 6 rate constants. Additionally, 5 para-
meters for GPx, and 8 parameters for HEDH needed
to be identified. Several of the values of the parameters
have been directly taken from other literature sources-
e.g. the Michaelis constant for glutathione (Km
GSH) for
glutathione peroxidase reaction [7], the rate constant of
LTA4 and HT degradation [23]. The values for other
parameters were chosen on the basis of the best coinci-
dence between modeling results and corresponding ex-
perimental data. To select the values of the parameters
we used the algorithm of fitting based on the Hook-Jeeves
method [35] implemented in the DBSolve Optimum pack-





vi  við Þ2 ð28Þ
Here, n is the total number of experimental points, iv
is the experimentally measured value of the variable or
reaction rate, vi is the value of the variable or reaction


















Kd3 1.3 10-4 -
klo 4.6 103 1/min
k3 0.34 103 (min· μM)-1
kox 2.7 10-4 (min· μM)-1
kox2 67.2 (min· μM)-1
kr 2.54 10-4 1/min
kr2 4.4 10-5 1/min
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sponding to the experimental ones.
Given the complexity of the model, simultaneous
identification of parameter estimates would be challen-
ging. Therefore, parameter identification was per-
formed individually for each enzyme by fitting to
literature data sets pertinent to the specific enzyme.
For example, the parameters of 5-LO were identified
via fitting of the 5-LO model against more than 10 ex-
perimentally measured curves (76 experimental points)
[22,24-26,37,38], 4 unknown parameters of GPx were
identified on the basis of 12 experimentally measured
points [39] and the parameters of HEDH have been
fitted against 47 experimental points [9].
Results and discussion
Modeling of 5-LO kinetics
The “LOS model” and parameter values identified during
model building enabled us to reproduce various experi-
mental data on the kinetics of 5-LO. Due to the large
number of fits only selected representative examples are
presented in the main text. The values of the parameters
obtained are given in Table 1. Figure 4 demonstrates a
model generated curve fitted to the experimentally mea-
sured dependencies of HP production rate on AA [24].
Based on this it was concluded that the model of 5-LO
satisfactorily described the observed non-monotonic be-
havior. Figure 5 demonstrates the simulated time series of
total concentration of HP and HT fitted to literature data
[37]. Additionally, our model satisfactorily fitted experi-
mental data on LTA4 production from endogenous and
exogenous HP (see Figure 6) [26] and the Ca2+ depend-
ence of 5-HP production by 5-LO on Ca2+ concentration
[38]. In the latter example the model satisfactorily
reproduced both the EC50 value (2–3 μM) and the
non-monotonic shape of the experimentally measured
dependence (see Figure 7). Other results of fitting are
summarized in Additional file 1: Appendix 6.
The next step of model evaluation examined its ability
to reproduce experimentally measured data which had
not been used for parameter identification. As an ex-
ample we selected a dataset describing the influence of
glutathione on 5-LO. In accordance with the experimen-
tal data [40], the effect of glutathione on 5-LO products
in a cell-free extract strongly depends on the concentra-
tion of AA. Under conditions of low AA concentrations,
the reaction rate of 5-LO is inversely proportional to the
glutathione concentration. When AA concentration is
high, the rate of 5-LO catalyzed reactions do not de-
crease even at high concentrations of GSH. Figure 8
demonstrates that our “LOS model” satisfactorily repro-
duces this threshold influence of GSH on the total con-
centration of “5-LO metabolites” (sum of HP, HT and
LTA4) at various concentrations of AA. Our modelexplains this phenomenon (threshold like response to
GSH increase at various AA concentrations) as driven by
the lack of lipid peroxides in this cell-free extract system
under conditions of low AA concentrations. In this case
the main agent responsible for 5-LO oxidation is HP (see
reaction r6 in Figure 3). HP acts as an electron acceptor
in the pseudo-peroxidase reaction converting 5-LO from
inactive (Fe2+) to active (Fe3+) state. Under conditions of
low AA concentrations, 5-LO is unable to produce a suf-
ficient quantity of HP molecules to drive the transition of
the enzyme to active form. Additionally data from experi-
ments with PMN homogenates [40] demonstrated that
the addition of GSH can, however, suppress the
Figure 4 Dependence of rate of HP synthesis on AA
concentration [24]. Experimental conditions: 0.2 mM ATP, 0.3 mM
CaCl2. Dots correspond to experimental data; solid line is model
generated curve.
Figure 6 The effect of exogenous HP on the formation of
deuterated LTA4 hydrolysis products. Human leukocyte
homogenate supernatant was incubated with 100 μM
octadeuterated arachidonic acid and 80 μM of the exogenous HP,
from left to right: LTA4 in the absence of endogenous HP,
deuterated LTA4 in presence of exogenous HP, LTA4 formed from
exogenous HP, total amount of 5-LO products HP and HT in the
absence of exogenous HP.
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remains below a critical limit.
Modeling of the response to redox and non-redox
inhibitors of 5-LO
We applied the “LOS model” to study the influences of
redox and non-redox inhibitors on the operation of 5-
LO. Inhibitor PF has been profiled in stimulated human
whole blood (HWB) against several relevant human tar-
gets including 5-LO, 12-LOX, 15-LO and COX enzymes
[18]. The compound completely inhibited the synthesis
of the 5-LO products (HT, oxoETE, LTB4 and LTE4)
with estimated IC50s between 100 and 190 nM. These
data demonstrate that the non-redox inhibitor PF is
6–10 times more potent than zileuton.
The mechanism of 5-LO inhibition by the redox and
non-redox inhibitors has been modeled under LTA4
steady-state concentration (Additional file 1: Appendix 1).Figure 5 Time dependence of cumulative concentration of HP
and HT. Experimental conditions: 20 μM of AA, 100 μM of Ca,
0.5 mg of 5-LO in the volume of 500 μL [25]. Dots correspond to
experimental data; solid line is model generated curve.Parameter values describing the kinetic properties of
redox and non-redox 5-LO inhibitors were chosen in such
a way to provide satisfactory coincidence between the
IC50 and IC80 measured experimentally [18] and those
calculated by the “LOS model”.
To validate the model describing 5-LO we again uti-
lized comparison of test data sets to simulated outcomes.
Examples of such “independent” data sets were
(i) time dependences of HP and HT measured at
various zileuton concentrations in in vitro
experiments with 5-LO [3].
(ii) time dependences of peroxides measured in the
presence and absence of PF and zileuton in ex vivo
experiments [18].
Figure 9 demonstrates that the derived values of para-
meters (Table 1) for zileuton on 5-LO allowed the model
to satisfactorily reproduce experimentally measured pro-
duction of the sum of HP and HT [3]. Moreover,
the “LOS model” qualitatively reproduced experimental
kinetic data describing the application of redox and
non-redox inhibitors in vitro. Experiments in a crude
cell lysates 5-LO system containing 10 μM of peroxide
(13(S)-HpODE) examined the addition of 10 μM of
zileuton or PF (reference). The “LOS model” satisfactory
reproduced peroxide consumption following zileuton, and
the absence of effect following PF application (Figure 10)
due to its non-redox mechanism [18].
Thus, comparison of the model simulations to two sets
of experimental data which were not used in parameter
identification enabled us to conclude that our model
adequately described the influence of inhibitors on the
system behavior.
Figure 7 Dependence of the HP production on the Ca concentration. Experimental conditions: 20 μM of AA, 0.1 mM ATP. Dots correspond
to experimental data from [38], line correspond to results of calculations.
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As have already been discussed earlier, the redox state of
the cell (GSH and lipid peroxide concentration) is able
to significantly influence 5-LO activity. In the “LOS
model” different levels of oxidative stress were described
in terms of LOOH (representing total peroxide concen-
tration except HP). To predict system responses to
redox and non-redox inhibitors and to identify possible
differences between them at different levels of LOOH
we simulated the dependence of steady state LTA4 and
oxoETE on PF and zileuton concentration. Several
LOOH concentrations were chosen for this study: 0 µM
(no oxidative stress), 5 µM (normal level according to
available literature data [41]), 10 µM (asthmatic patientsFigure 8 Simulation of influence of glutathione on production
of 5-LO metabolites (sum of LTA4, HP and HT). Parameters of the
LOS model used for simulation: pool of NADP 3 mM; NADPH 2 mM;
Ca 1 mM; 5-LO 0.1 μM; HEDH5 0.1 μM; Values of parameter PL
responsible for steady state AA level are 117 (solid), 120 (dash),
125 (dot).[41]) and 100 µM (extremely high oxidative stress). For
all simulations the system was run to steady-state condi-
tions with subsequent addition of inhibitor and the effect
at the new steady-state noted. This was represented as
the percentage of inhibition of LTA4 and oxoETE at a
given inhibitor concentration and was calculated using
the following equations:













ð30ÞFigure 9 Dependence of sum of the concentrations of HP and
HT on time in presence of zileuton. Experimental conditions: with
no 5-LO inhibitor applied ((squares – data, solid line – model
results), with 5 μM of Zileuton applied (triangles – data, dashed line
– model results)) and with 20 μM of Zileuton applied (circles – data,
dotted line – model results) [3]. Other concentrations: 20 μM of AA,
0.4 mM of Ca.
Figure 10 Quantitative simulation of experiment [18] with different inhibitors. Consumption of 10 μM HP by 5-LO system in presence of
10 μM PF (dotted line) or 10 μM Zileuton (solid line) or in the absence of inhibitors (dashed line, coinciding with dotted line). Concentrations: PL
40 μM, pool of glutathione 10 mM, GSH 5 mM. Other parameters are as in the legend to Figure 8.




of LTA4 and oxoETE at a specified inhibitor concentra-
tion LTA4st
inh = 0, oxoETEst
inh = 0 are steady-state concentra-
tions of LTA4 and oxoETE in the absence of inhibitor.
We have simulated how the LTA4 and oxoETE dose
response depends on the LOOH level and found that
both were influenced significantly (Table 2). Indeed,
assuming LOOH level equal to 0 (no oxidative stress)
we have simulated how steady state concentrations of
LTA4 and oxoETE depend on zileuton and PF compound
concentrations (Figures 11–12, solid lines). Figure 11
demonstrates that model fits satisfactorily ex vivo experi-
mental data [18] on the dependence of LTA4 and
oxoETE on PF concentration (Tables 3, 2). The solid lines
on Figures 11–12 also show that the potency of zileuton
to inhibit oxoETE production is the same as for LTA4
production, but it is ten times lower than the potency of
PF compound to inhibit both rates (see Tables 3, 2).
Assuming a level of LOOH in healthy controls of





IC50 for inhibition by
Zileuton (nM)
IC50 for inhibition by
PF-4191834(nM)
For LTA4 For 5oxoETE For LTA4 For 5oxoETE
0 980 962 122 125
5* 860 1145 125 129
10** 860 1410 143 146
100 1450 12670 290 300
*- corresponds to healthy subjects.
** - corresponds to asthmatic subjects.that curves describing level of inhibition of LTA4 and
oxoETE show a similar tendency but in case of inhibition
with zileuton a new feature was observed. The increase
in LOOH level from 0 to 5 µM was accompanied by a de-
crease in zileuton potency for inhibition of oxoETE syn-
thesis (see Figure 12, dashed line) in comparison with its
potency to inhibit LTA4 synthesis (IC50LTA4<IC50oxoETE).
This effect is more pronounced when setting the
[LOOH] equal to 10 µM (approximating that of asth-
matic patients, Figures 11–12, dotted lines). To further
illustrate this effect we simulated the impact of a
supra-physiological LOOH concentration of 100 µM on
the inhibitory properties of compounds (dash-dot lines
in Figures 11b and 12b).
Discussion of redox-inhibitor properties at high oxidative
stress
Zileuton donates an electron to the active (Fe3+) state of
5-LO to form the inactive ferrous (Fe2+) state and a
zileuton radical (see reaction r7 in Figure 3). The zileu-
ton radical is eliminated without subsequent reduction
to zileuton [42]. To activate 5-LO it is necessary to
oxidize the inactive ferrous (2+) state, i.e. an electron
donated to an acceptor such as HP or LOOH. Therefore,
under conditions of low LOOH only HP is able to
oxidize 5-LO. If zileuton is applied, 5-LO is converted to
the inactive ferrous state, the rate of HP synthesis
decreases and, as a consequence, the enzyme is com-
pletely inhibited because of lack of its oxidation. In the
absence of other sources of lipid peroxides and HP, 5-LO
is completely inhibited by zileuton.
Under conditions of high LOOH, the transformation
of ferrous 5-LO state into ferric state can proceed in two
Figure 11 Simulation of influence of PF on LTA4 and oxoETE
production. Concentrations of lipid peroxide (LOOH): 0 (solid), 5 μM
(dash), 10 μM (dot), 100 μM (dash-dot). Other parameters are as in
the legend to Figure 10.
Figure 12 Simulation of influence of zileuton on LTA4 and
oxoETE production. Concentrations of lipid peroxide (LOOH): 0
(solid), 5 μM (dash), 10 μM (dot), 100 μM (dash-dot). Other
parameters are as in the legend to Figure 10.
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action r6 in Figure 3). When zileuton is applied, the con-
centration of ferrous state of 5-LO increases. However,
high level of LOOH may compensate for the lack of HP
in the pseudo-peroxidase reaction that leads to mainten-
ance of level of the active 5-LO state and, as a conse-
quence, the lipoxygenase reaction occurs. Under these
conditions the rate of pseudo-peroxidase reaction
increases and both HP and LOOH are reduced in this
reaction converting 5-LO into active ferric state. As aTable 3 Potency of 5-LO inhibitors in whole blood from contr
CONTROL
IC50 (nM) IC80 (nM)
Experim. Model Experim. Mo
Zileuton 850 ± 220 860 2270 ± 710 33
PF-4191834 120 ± 10 125 300 ± 20 5consequence of increased HP consumption in the
pseudo-peroxidase reaction, its concentration decreases,
leading to a decrease in LTA4 production. At the same
time increases in HT concentration produced in the
pseudo-peroxidase reaction leads to further increase in
oxoETE production.
Conclusions
We have constructed a model of 5-LO activity and regu-
lation that demonstrates emergent properties consistentol (Normal) and asthmatic human volunteer [18]
ASTHMATICS
IC50 (nM) IC80 (nM)
del Experim. Model Experim. Model
30 1080 ± 220 860 2520 ± 1010 3270
18 180 ± 20 143 390 ± 50 550
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model we have derived several conclusions:
i) Both redox and non-redox inhibitors of 5-LO decrease
LTA4 production independently of lipid peroxide level.
ii) Non-redox inhibitors of 5-LO decrease HT
production (and, consequently, 5-oxoETE)
independently of lipid peroxide level.
iii) The effect of redox inhibitors on oxoETE
production strongly depends on LOOH level;
iv) Redox inhibition of 5-LO under condition of high
LOOH switches 5-LO from LTA4 production to
HT (and, consequently, oxoETE) production.
OxoETE is one of the key inflammatory mediators and
the results of our work presented in the paper have
demonstrated that under certain conditions redox inhi-
bitors can lead to a non-intuitive increase in oxoETE
synthesis. Together with the PK disadvantages of zileu-
ton this observation supports the further investigation of
non-redox inhibitors as possible drugs against asthma.
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